Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA 'Medical Innovation Development Plan' Outlined By Gottlieb

Executive Summary

Testifying before Senate subcommittee, FDA commissioner put his plans for facilitating new drug development front and center, a shift from his many past discussions about generic drug development.

Advertisement

Related Content

White House Slams Generic Exclusivity Provisions In User Fee Bill
White House Slams Generic Exclusivity Provisions In User Fee Bill
Master Protocols Are Both Welcome And Inevitable – US FDA's Woodcock
Generic Program Is Biggest Extra Item In Senate User Fee Reauthorization Bill
Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood
Gottlieb Distances Himself From Trump's User-Fee Heavy Budget
Brand Exclusivity 'Gaming' To Be Addressed At US FDA Meeting
Opioid Policy At US FDA To Become 'More Forceful,' Gottlieb Says
Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications
Disease 'Subsetting' Not Driving Jump In Orphan Designations, US FDA Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120915

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel